SOFA – Page 13 – Communicable Diseases Research

A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-07-132022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 24 hour 48 hour Activation acute lung injury acute pneumonia acute respiratory distress syndrome Administered Adult age all-cause mortality Amendment antibodies antibody Antibody test anticipated antiviral therapy approval ARDS assessment assigned baseline Biomarker Blood cardiac disease Care change class Clinical improvement clinical study clinical trial complement Complement inhibitor component Computed tomography concealed Concentration conducted Confirmed Controlled coronary syndrome COVID-19 criteria current Day diagnosis of SARS-CoV-2 dialysis discharge dissemination dose Duration Efficacy element eligibility Endotracheal intubation EU Clinical Trial EudraCT evaluate the effect expected failure female patient Final fraction France Germany greater half-live hospital Hospitalization humanized Hypercoagulable state Immunoglobulin Infection Inflammatory inhibitor initiated intensive care Intubated intubation invasive Invasive mechanical ventilation investigator IVIG Japan Lung injury mechanical ventilation medication monoclonal multicenter Neisseria meningitidis Non-invasive number objective Open-label original outcome oxygen participant Patient patients randomized patients with COVID-19 Period peripheral capillary phase Placebo Pneumonia polymerase chain positive airway pressure presenting progression protocol randomised randomised controlled trial randomization randomization list Randomized randomized controlled study Randomly Ravulizumab receive recruitment registry Remdesivir renal respiratory respiratory distress Respiratory distress syndrome routine clinical care Safety screened Screening secondary Serious Adverse Events serum severe acute respiratory distress syndrome coronavirus 2 Severe acute respiratory syndrome severe COVID-19 severe pneumonia SOFA Spain SpO2 Sponsor stratified Study protocol supportive care survival The United States therapy time Treatment treatment-emergent adverse event Ultomiris United Kingdom ventricular Viral website with COVID-19 X-ray
[DOI] 10.1186/s13063-020-04548-z PMC 바로가기 [Article Type] Letter

Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study

Research Paper

Published on 2020-06-302022-10-28
Journal: Aging (Albany NY) [Category] COVID-19, SARS,

[키워드] addition Admission Analysis APACHE II AST AUC BNP Community coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 severity CRP cutoff value defined help identify Illness severity independent risk factor Inflammatory response lactate dehydrogenase (LDH) LDH Lung injury lymphocyte Lymphocytes median age P/F ratio parameters Patient Pneumonia positively correlated Predictive public health emergency Renmin Hospital retrospective risk factor severe cases severe COVID-19 severity of COVID-19 significantly Society SOFA SOFA scores specificity univariable university World Health Organization Wuhan
[DOI] 10.18632/aging.103372 PMC 바로가기 [Article Type] Research Paper

Sociodemographic, clinical and laboratory factors on admission associated with COVID-19 mortality in hospitalized patients: A retrospective observational study

Research Article

Published on 2020-06-252022-10-28
Journal: PLoS ONE [Category] COVID-19, MERS, SARS,

A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol

Letter

Published on 2020-06-082022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 24 hour 28-day mortality activated acute respiratory distress syndrome Administered Admission adverse effect age albumin allergic allocation concealment Anticoagulant apheresis approval approved assessment Basel block size C-reactive protein category changes in city Coagulopathy Control COVID-19 COVID-19 disease criteria Cytokine release syndrome D-dimer defined disease dissemination drug eight element Enrollment evaluate evaluated ferritin fibrinogen first dose FIVE food function group ICU ICU admission ill patient Improving Inc. Inflammatory ingredient intensive care intensive care unit International Intervention intervention group intubation IRB ISRCTN KDIGO King Kingdom Laboratory lack lactate dehydrogenase life threatening life-threatening Life-threatening COVID-19 marker measure Mild Ministry of Health Multicenter trial Multisystem organ failure National negative RT-PCR normalized number objective occur on mechanical ventilation Open-label outcome Palliative care participant Participants Patient patients performed pilot study plasma primary site Prothrombin time protocol Qiagen randomization randomize Randomized Randomized controlled trial randomized trial Real-time PCR receive receiving recommendations recruit reduce replaced Roche RT-PCR RT-PCR kit Safety Sample size SARS CoV-2 SARS-CoV-2 SARS-COV-2 infection Saudi Arabia secondary serum Seven sodium SOFA status Stratification Study protocol supportive care Switzerland System Therapeutic plasma exchange therapy TPE treatment for COVID-19 tumor necrosis factor-alpha USA Volume website
[DOI] 10.1186/s13063-020-04454-4 PMC 바로가기 [Article Type] Letter

Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 active malignancy acute respiratory distress syndrome Administered administration age approval approved ARDS assessment automated Berlin blinded Cell cell suspension cellular changes in chronic liver disease class clinical Clinical diagnosis Clinical outcome clinical outcomes clinical trial comparator Compliance conducted control group Controlled trial COVID 19 COVID-19 COVID-19 pandemic declined defined described determine diagnosis of COVID-19 dissemination Donor Dose escalation driving Effect Efficacy element eligible Elizabeth enrolled ethics committee EudraCT excluded facilitate failure fixed dose hospital ICU incidence Inclusion increase in index individual information infusion intensive care unit Intervention Invasive mechanical ventilation investigator King’s College London London Mesenchymal stem cells Mesenchymal stromal cells MHRA moderate Mortality MSC MSCs NIHR number objective open label Other outcome pandemic PaO participant Patient patient population patients with ARDS PCR test PF ratio Phase 1 Phase 2 Placebo placebo-controlled protocol protocol amendment Public randomised randomised controlled trial REC receiving recruited recruitment repair reported Research respiratory Resuscitation Sample size secondary Secondary objective Secondary outcomes Serious Adverse Events severe ARDS single intravenous infusion SOFA solution Standard steering committee stratified stromal cell Study protocol Therapeutics therapy trauma Treatment Trial triple blinded Trust umbilical United Kingdom university Venous Thromboembolism Ventilation verbal Volume web-based randomisation system website WHO Withdrawal
[DOI] 10.1186/s13063-020-04416-w PMC 바로가기 [Article Type] Letter

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Research

Published on 2020-04-282022-11-01
Journal: JAMA [Category] COVID-19, SARS,

[키워드] acute respiratory distress acute respiratory syndrome Administered administration Admission age Antiviral antiviral agent Antiviral treatment approach ARDS assessment binding blood biochemical body temperature case sery change China Chinese patient clinical Clinical outcome clinical status clinical trials conducted convalescent plasma coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Critical Critically ill patient determine Dilution discharged ECMO Effectiveness ELISA end point enzyme-linked immunosorbent exposure extracorporeal membrane oxygenation failure Final finding Follow-up greater hospital Human plasma IgG Ill Importance Infection Infectious disease laboratory-confirmed limited sample size measure mechanical ventilation Methylprednisolone Mortality neutralization titer neutralizing antibody Neutralizing antibody titer normalized objective observation outcome pandemic participant Patient patients plasma Plasma transfusion Point preliminary finding progression raise randomized clinical trials receiving recovered patients Relevance resolved Result SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2–specific antibody serum antibody setting severe pneumonia Shenzhen SOFA SOFA score Study design Support syndrome therapeutic agent treated Treatment ventilatory Viral load were given with COVID-19 women
[DOI] 10.1001/jama.2020.4783 PMC 바로가기 [Article Type] Research

Clinical features, complications and mortality in critically ill patients with 2009 influenza A(H1N1) in Sfax,Tunisia

Article

Published on 2011-01-312023-06-23
Journal: Influenza and Other Respiratory Viruses [Category] 신종인플루엔자,

[키워드] 2009 influenza A(H1N1) intensive care multiple organ failure outcome SOFA
[DOI] 10.1111/j.1750-2659.2011.00196.x PMC 바로가기